Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Apple

AGCO

Applied Materials

Ares Management

D.R. Horton

Dick's Sporting Goods

Devon Energy

Ensign Group

EOG Resources

Comfort Systems USA

JPMorgan Chase & Co

Microsoft

Owens Corning

QUALCOMM

TFI International

Vistra Energy

Advanced Drainage Systems

We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income.

Earn A Potential 10% Plus Income With Monthly Options (March 2024)

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the TD Cowen 44th Annual Health Care Conference.

Merck to Participate in the TD Cowen 44th Annual Health Care Conference

Merck has received a letter that Hikma Pharmaceuticals US unit has sought a pre-patent expiry approval from the US FDA to sell a generic version of its Bridion injection, the drugmaker said in filing on Monday.

Merck's Bridion faces generic threat from drugmaker Hikma

Eli Lilly

Vericel

Pharma stocks and massive potential are synonymous. With horrible diseases like cancer, diabetes, and heart disease still a mile away from developing a cure, drugs that address these conditions command outrageous prices.

3 Top Pharma Stocks for Investors Betting on a Biotech Boom

Amid a frenzy for AI-related stocks, shares of a little-known biotech company in South Korea got an Nvidia-esque boost. Alteogen, a pharmaceutical company with nothing to do with AI, saw its share price jump about 25% Friday to an all-time high after it announced a licensing deal with drug giant Merck.

Merck Deal Boosts Founder Of Little-Known Korean Biotech Company Into Billionaire Ranks

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA, Merck's anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as a monotherapy as adjuvant treatment, for the treatment of resectable non-small cell lung cancer (NSCLC.

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

General Electric

Howmet Aerospace

Netflix

NVIDIA

Ralph Lauren

Stryker

Large growth stocks are dominating this year. But some investors are cashing in even faster in by finding the best-of-the-best growth S&P 500 stocks.

Investors Cash In Fast On 10 Large Stocks With Insane Momentum

Intuitive Surgical

Merck owns the best-selling drug in the world and has a plan to replace it once it runs out of patent exclusivity. Intuitive Surgical leads an industry that is difficult to penetrate and has plenty of opportunity for growth ahead.

2 Monster Stocks to Buy Without Any Hesitation

Allstate

Estee Lauder

Paramount Global

Stanley Black & Decker

Targa Resources

Tyson Foods

Investors are understandably jazzed about Nvidia's upcoming earnings report for last year. But analysts think a surprisingly large number of companies will grow even faster this year.

8 Companies' Profit Is Expected To Outgrow Even Nvidia's This Year

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Grants Priority Review to Merck's Application for KEYTRUDA Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma.

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Travelers

2 Dow Stocks That Have Been Most Overbought Since The 1970s

CF Industries Holdings

AT&T

Tuesday's U.S. Consumer Price Index ( CPI ) inflation report showed inflation rising faster than expected in January. The cost of housing increased by 0.6%, indicating underlying inflation pressures remain strong.

3 Inflation-Proof Stock Picks Following Tuesday's CPI Report

Bristol-Myers

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Johnson & Johnson

Pfizer

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

SPDR S&P Pharmaceuticals ETF

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs After Q4 Earnings

Novo Nordisk

Demand is surging for weight-loss treatments that are being rolled out by major pharmaceutical companies. Investors are still trying to assess the full market opportunity and competitive landscape.

Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month

Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher.

J&J, Merck and Bristol Myers CEOs, under fire on Capitol Hill, seek to turn up heat on drug-market middlemen

Chief executives from three major pharmaceutical companies will testify before a Senate committee on Thursday, following a back-and-forth with Sen. Bernie Sanders (I-Vt.

Pharma CEOs Will Testify Today Over Prescription Drug Prices: Here's What To Watch For

The push to cut drug prices is one of those rare hot-button issues that unites the two major political parties.

Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricing

Lawmakers seeking to hold drugmakers accountable for high prescription-drug costs are focusing on some prices that shed little light on the problem, drug-pricing experts say.

Merck, J&J and Bristol Myers CEOs face drug-pricing grilling on Capitol Hill, but experts cite deeper problems under the radar

Merck's (MRK) Animal Health unit is set to strengthen its position with the acquisition of Elanco Animal Health's aqua business for $1.3 billion. The transaction is expected to close by mid-2024.

Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3B

Southwest Airlines

Seagate Technology Holdings PLC

Earnings season is well underway, and the winner-and-loser separation continues to grow. Of the companies that beat consensus analyst estimates, even fewer go well beyond and exceed analyst expectations.

3 companies that more than doubled analyst EPS estimates

Elanco Animal Health Inc

Elanco Animal Health Inc has announced the sale of its aqua business to Merck Animal Health for US$1.3 billion in a bid to refocus on other markets. This will enable Elanco to accelerate debt paydown by US$1.05 billion to US$1.1 billion, the company said on Monday, with the proceeds representing over seven times the estimated 2023 revenue of the hot and cold water species product firm.

Elanco Animal Health sells aqua business to Merck for $1.3 billion

Merck struck a deal to buy Elanco Animal Health's aqua business in a deal that expands the drugmaker's animal-health business.

Merck to Buy Elanco's Aqua Business for $1.3 Billion

Merck said on Monday it had agreed to buy Elanco Animal Health's aqua business for $1.3 billion in cash, to strengthen its portfolio of aquatic healthcare products.

Merck to buy Elanco Animal Health's aqua business for $1.3 bln

Elanco Animal Health Inc. ELAN, -0.41% said Monday it has agreed to sell its aqua business to Merck Animal Health MRK, +0.02% for $1.3 billion in cash. Greenfield, Ind.

Elanco Animal Health agrees to sell aqua business to Merck for $1.3 billion in cash

News for Merck Stock (MRK)